Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Schmid, Peter; Cortes, Javier; Dent, Rebecca; L. McArthur, Heather; Pusztai, Lajos; Kümmel, Sherko; Denkert, Carsten; Hee Park, Yeon; Hui, Rina; Harbeck, Nadia; Takahashi, Masato; Im, Seock‐Ah; Untch, Michael; A. Fasching, Peter; Mouret‐Reynier, Marie‐Ange; Foukakis, Theodoros; Ferreira, Marta; Cardoso, Fátima; Zhou, Xuan; Karantza, Vassiliki; Tryfonidis, Konstantinos; Aktan, Gursel; O’Shaughnessy, Joyce

doi:10.1056/nejmoa2409932

Public

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Published in New England Journal of Medicine • Sep 15, 2024

Authors:

Peter Schmid

Javier Cortes

Rebecca Dent

Abstract

BACKGROUND: In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing chemotherapy. Here we report the final results for...

Subject

Pembrolizumab

Oncology

Triple-negative breast cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!